• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine.

作者信息

Sakurai Aki, Nakazato Tomonori

机构信息

Department of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.

出版信息

Leuk Lymphoma. 2020 Dec;61(12):2995-2997. doi: 10.1080/10428194.2020.1791847. Epub 2020 Jul 11.

DOI:10.1080/10428194.2020.1791847
PMID:32654579
Abstract
摘要

相似文献

1
The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia related changes treated with azacitidine.阿扎胞苷治疗的骨髓增生异常综合征及伴有骨髓增生异常相关改变的急性髓系白血病患者中控制营养状态评分的预后价值
Leuk Lymphoma. 2020 Dec;61(12):2995-2997. doi: 10.1080/10428194.2020.1791847. Epub 2020 Jul 11.
2
The geriatric nutritional risk index predicts the early death and survival in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Hematol Oncol. 2020 Oct;38(4):611-613. doi: 10.1002/hon.2760. Epub 2020 Jun 24.
3
The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.纤维蛋白原-白蛋白比值指数在接受阿扎胞苷治疗的伴骨髓增生异常相关改变的骨髓增生异常综合征和急性髓系白血病患者中的预后价值。
Ann Hematol. 2021 Apr;100(4):953-957. doi: 10.1007/s00277-021-04440-z. Epub 2021 Feb 1.
4
Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.糖原合成酶1（GYS1）、巨噬细胞移动抑制因子（MIF）和原癌基因（MYC）的过表达与骨髓增生异常综合征和急性髓系白血病的不良预后及对阿扎胞苷反应不佳相关。
Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):236-44. doi: 10.1016/j.clml.2014.10.003. Epub 2014 Oct 23.
5
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia.阿扎胞苷对急性髓系白血病异基因干细胞移植后复发患者的临床活性。
Haematologica. 2016 Jul;101(7):879-83. doi: 10.3324/haematol.2015.140996. Epub 2016 Apr 14.
6
Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.针对比利时骨髓增生异常综合征、急性髓系白血病或慢性粒单核细胞白血病患者的阿扎胞苷获取计划。
Curr Med Res Opin. 2015 Jan;31(1):35-42. doi: 10.1185/03007995.2014.972499. Epub 2014 Oct 17.
7
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.一项关于地西他滨治疗阿扎胞苷治疗失败后的高危骨髓增生异常综合征和低原始细胞数急性髓系白血病的 II 期研究。
Haematologica. 2019 Aug;104(8):1565-1571. doi: 10.3324/haematol.2018.207118. Epub 2019 Feb 7.
8
Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.阿扎胞苷治疗相关性骨髓增生异常综合征和急性髓系白血病中的克隆选择。
Eur J Haematol. 2020 May;104(5):488-498. doi: 10.1111/ejh.13390. Epub 2020 Mar 9.
9
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.高危骨髓增生异常综合征和急性髓系白血病患者序贯使用阿扎胞苷和来那度胺：一项单臂1/2期研究。
Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.
10
[CME myelodysplasia - a frequent hematologic neoplasia in the elderly].[细胞介导的髓系发育异常——老年人中常见的血液系统肿瘤]
Praxis (Bern 1994). 2014 May 21;103(11):617-27. doi: 10.1024/1661-8157/a001667.

引用本文的文献

1
The controlling nutritional status score as a predictor of survival in hematological malignancies: a systematic review and meta-analysis.作为血液系统恶性肿瘤生存预测指标的控制营养状况评分：一项系统评价和荟萃分析
Front Nutr. 2024 Jun 13;11:1402328. doi: 10.3389/fnut.2024.1402328. eCollection 2024.
2
Prognostic impact of the controlling nutritional status score in patients with hematologic malignancies: A systematic review and meta-analysis.血液恶性肿瘤患者控制营养状态评分的预后影响：系统评价和荟萃分析。
Front Immunol. 2022 Oct 5;13:952802. doi: 10.3389/fimmu.2022.952802. eCollection 2022.
3
Prognostic value of the controlling nutritional status score in patients with myelodysplastic syndromes.
控制营养状况评分在骨髓增生异常综合征患者中的预后价值。
Front Nutr. 2022 Jul 27;9:902704. doi: 10.3389/fnut.2022.902704. eCollection 2022.
4
The prognostic value of the controlling nutritional status score in patients with myelodysplastic syndrome.控制营养状况评分在骨髓增生异常综合征患者中的预后价值。
Support Care Cancer. 2022 Nov;30(11):8997-9002. doi: 10.1007/s00520-022-07313-x. Epub 2022 Aug 8.
5
Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine.后基因组时代的骨髓增生异常综合征及精准医学的未来展望
Cancers (Basel). 2021 Jun 30;13(13):3296. doi: 10.3390/cancers13133296.